Form 4: Nautilus Biotechnology Chief Scientist Granted Stock Options
SEC Form 4 Filing
Parag Mallick, Chief Scientist of Nautilus Biotechnology, was granted stock options for 280,000 shares on March 3, 2025, according to a Form 4 filing.
Summary
- A Form 4 filing reveals that Parag Mallick, the Chief Scientist of Nautilus Biotechnology, Inc., received stock options.
- On March 3, 2025, Mallick was granted options to purchase 280,000 shares of Nautilus Biotechnology's common stock at an exercise price of $1.24 per share.
- The options vest over a period of 48 months, with 25% vesting on the first anniversary of the Vesting Commencement Date (January 1, 2025) and the remaining balance vesting monthly thereafter.
- Mallick also granted power of attorney to several individuals to handle SEC filings related to company securities.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.
Positives
- The granting of stock options to a key executive like the Chief Scientist can be seen as a positive incentive for continued service and contribution to the company's success.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with those of the shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in biotech companies.
- The vesting schedule of 4 years with a one-year cliff is also a common practice to ensure long-term commitment.
- Comparable companies such as Adaptive Biotechnologies and Pacific Biosciences also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Scientist to contribute to the company's long-term success.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| February 21, 2025 | Date of execution for the Power of Attorney. |
| January 1, 2025 | Vesting Commencement Date for the stock options. |
| March 3, 2025 | Date of the stock option grant. |
| March 4, 2025 | Date of the Form 4 filing. |
| January 1, 2026 | First vesting date for 25% of the stock options. |
| March 3, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.